INTRODUCTION

Lung cancer is the number one cause of cancer-related death among both men and women worldwide.\(^1\) Non-small cell lung cancer (NSCLC) accounts for approximately 85% of lung cancer cases.\(^2\) NSCLC is histologically divided into three subtypes of which lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) account for ~50% and ~40% of the cases respectively.\(^3\) Unfortunately, most of the NSCLC patients are diagnosed at advanced stages and have a very poor prognosis, which consequently results in a low overall survival (OS) rate (15%).\(^4,5\) In this regard, LUAD is one of the most aggressive and deadliest types of cancer with less than 5 years of OS.\(^6\) A variety of factors such as cigarette smoking, exposure to second-hand smoke, air pollution, cooking fumes, asbestos and radon put individuals at the risk of LUAD. Besides, immunologic dysfunction, genetic susceptibility as well as some diseases including asthma and tuberculosis infections would enhance the risk of LUAD.\(^7\) Additionally, it is reported that the carcinogenesis of LUAD varies between men and women as well as between smokers and never smokers.\(^8\)

Long non-coding RNAs (lncRNAs) refer to a class of non-protein coding transcripts that are involved in several regulatory processes and are considered as potential biomarkers for almost all cancer types. This study aims to investigate the prognostic value of lncRNAs for lung adenocarcinoma (LUAD), the most prevalent subtype of lung cancer. To this end, the processed data of The Cancer Genome Atlas LUAD were retrieved from GEPIA and circLncRNA.net databases, matched with each other and integrated with the analysis results of a non-small cell lung cancer plasma RNA-Seq study. Then, the data were filtered in order to separate the differentially expressed lncRNAs that have a prognostic value for LUAD. Finally, the selected lncRNAs were functionally annotated using a bioinformatic and systems biology approach. Accordingly, we identified 19 IncRNAs as the novel LUAD prognostic IncRNAs. Also, based on our results, all 19 IncRNAs might be involved in lung cancer-related biological processes. Overall, we suggested several novel biomarkers and drug targets which could help early diagnosis, prognosis and treatment of LUAD patients.

KEYWORDS
bioinformatics, functional annotation, lung adenocarcinoma, prognostic lncRNAs, systems biology
well-known oncogenic lncRNA that is up-regulated in several cancers.\textsuperscript{11} The lncRNA linc00665 has recently been represented as an oncogenic factor in LUAD.\textsuperscript{12} However, there are hundreds of lncRNAs that their exact roles in different cancers are yet to be discovered and/or experimentally validated. RAB6C-AS1, for instance, is a poorly known lncRNA that is presented as a potential candidate biomarker for prostate and brain cancers but its implications in the carcinogenesis of these cancers are not still neither computationally nor experimentally examined and validated.\textsuperscript{13} LncRNAs are also involved in the tumourigenesis and progression of lung cancer through aberrant regulation of gene expression at the transcriptomic, epigenomic and genomic levels.\textsuperscript{14} Additionally, epigenetic and RNA deregulations are considered as a potential hallmark of LUAD.\textsuperscript{15} Altogether, discovering the functional roles of lncRNAs in LUAD would greatly enhance our knowledge of the aetiology of LUAD and lead to the advent of novel promising biomarkers and drug targets for this deadly disease.

As lncRNAs play essential roles in the progression of different cancers, they have the potential to be used as diagnostic and prognostic biomarkers.\textsuperscript{16} Also, the presence of several circulating transcripts has been reported in the plasma and serum of cancer patients which could be used for diagnostic purposes.\textsuperscript{17} Moreover, different circulatory non-coding RNAs (ncRNAs) including lncRNAs are being constantly represented as biomarkers for cancer diagnosis, prognosis and monitoring of treatment response.\textsuperscript{5,18} Thus, lncRNAs are potential factors for the prediction of OS and disease-free survival (DFS) periods of cancer patients. Today, lncRNAs are being regarded as potential diagnostic factors and therapeutic targets for NSCLC.\textsuperscript{19} The lncRNA LINC00578, as an example, is represented as a promising biomarker and therapeutic target for LUAD.\textsuperscript{20} In another study, TG et al introduced three lncRNAs including HCP5, SNHG12 and LINC00472 as potential biomarkers for LUAD management.\textsuperscript{21} Also, several lncRNAs such as LHFPL3-AS2, LIN01105, LIN00092, LIN00908 and FAM83A-AS1 have been reported as prognostic factors for LUAD.\textsuperscript{22} Furthermore, the diagnostic value of circulating lncRNAs as plasma signatures for the early detection of lung cancer has been confirmed.\textsuperscript{23}

A growing number of computational models are being constantly developed for the identification of lncRNA-disease associations and characterization of functional roles of lncRNAs in diseases including lung cancer. KATZLDA, as an example, is a robust computational model for the prediction of lncRNA-disease associations.\textsuperscript{24} In another study, Chen et al proposed a kind of top-down model. They assumed that similar diseases tend to be associated with functionally similar lncRNAs and accordingly, developed a computational model named LRLSLDA.\textsuperscript{25} Generally speaking, identification of lncRNA-disease associations is achieved based on two different approaches; using known lncRNA-disease associations, as in machine learning-based and network-based models, or using models based on the known disease-related genes/miRNAs. Functional similarity calculation method, which is based on the assumption that functionally similar lncRNAs are associated with similar diseases, is commonly applied in both of the aforementioned approaches but usually in combination with other methods.\textsuperscript{26} Various information resources are used for the calculation of lncRNA functional similarity which could be summarized into four categories: lncRNA expression similarity, GO term-based lncRNA functional similarity, miRNA/mRNA-lncRNA interaction-based functional similarity and lncRNA-disease association-based functional similarity.\textsuperscript{27} In the current study, a GO term-based lncRNA functional similarity method was used to functionally interrogate the lncRNA-LUAD associations. In the context of the prediction of functional roles of lncRNAs in diseases, several computational models have thus far been proposed that could be classified into four major categories, including gene coexpression-based models, lncRNA-miRNA/mRNA/protein interaction-based models, sequence alignment-based models and integrative features-based models which incorporates sequence-derived and experimental features of lncRNAs.\textsuperscript{27}

In this study, we applied a coexpression-based model for the prediction of functional roles of lncRNAs in LUAD. It is frequently reported that lncRNAs are differentially expressed (DE) in cancer tissues.\textsuperscript{28} Also, according to the guilt by association principle, if a gene shows an expression correlation with the expression profiles of a set of genes involved in a specific function, that gene is possibly involved in the same function.\textsuperscript{29} Therefore, identification of the coexpressed genes (CEGs) of DE-lncRNAs can help functional annotation of lncRNAs in cancer. Moreover, CEGs can have common regulatory sequences and might be interacting partners of the same complex and/or involve in the same pathway.\textsuperscript{30} Actually, dysregulated lncRNAs interact with other macromolecules and consequently drive various cancer manifestations.\textsuperscript{31} Hence, identification of the CEGs of DE-lncRNAs in cancer assists in the characterization of oncogenic or tumour suppressive functions of lncRNAs and recognition of pathways they are involved in. This is a common methodology that can be used for the functional annotation of poorly known genes in the context of different diseases including cancer.\textsuperscript{32}

There are several notable variances in the gene expression profile and molecular features between LUSC and LUAD and consequently different therapeutic strategies and regiments are administrated to these two major subtypes of NSCLC.\textsuperscript{33} Thus, NSCLC studies should precisely target either LUAD or LUSC so as to get more specific results. In this study, we systematically analysed the prognostic value of lncRNAs for LUAD and annotated their functional roles using a bioinformatic and systems biology approach. A schematic outline of the implemented methodology is given in Figure 1.
2 | METHODS

2.1 | Data preparation

All of The Cancer Genome Atlas (TCGA) LUAD DE-lncRNAs (\(1 < \left| \log_{2}FC \right| \); adjusted P-value (adjp) < 0.05) were retrieved from the circlncRNA.net (Table S1).34 The circlncRNA.net is an integrated web-based resource for mapping functional networks of long or circular forms of ncRNAs. TCGA LUAD is one of the projects conducted by TCGA Research Network and comprises 483 LUAD tumour samples and 59 normal lung samples. Also, all TCGA LUAD DEGs were obtained from GEPIA (Table S2).35 GEPIA is a web server specialized for analysing the RNA-seq data of 9736 tumours and 8587 normal samples from the TCGA and the GTEx projects. In the context of the differential expression analysis of genes in LUAD, GEPIA has added 288 normal lung samples from GTEx projects to the normal samples of TCGA LUAD so as to make a higher balance between the number of normal and cancer samples. Then, common DE-lncRNAs between circlncRNA.net and GEPIA with the same expression dysregulation (either over- or underexpression) in both databases were selected. Moreover, a total of six plasma RNA-seq data samples, including three normal and three NSCLC plasma samples, were retrieved from the PRJNA286036 study at the European Nucleotide Archive and analysed using an Australian Galaxy server (GVL QLD; GVL 4.0.1; https://galaxy-qld.genome.edu.au/galaxy).
2.2 | RNA-seq data analysis

We applied the following pipeline with this exact sequence of steps for analysing the plasma RNA-seq data obtained from the European Nucleotide Archive: reads were mapped to the hg19 reference genome using STAR\textsuperscript{36}; lncRNA transcripts were assembled using Cufflinks\textsuperscript{37} according to the GTF (UCSC compatible) GRCh37/hg19 Version 5.0 full database annotation file downloaded from the LNCipedia\textsuperscript{38,39}; all Cufflinks’ GTF output files and the LNCipedia GTF file were merged using Cuffmerge\textsuperscript{37}; read counts were calculated using the SAM/BAM to count matrix tool based on the HTSeq code\textsuperscript{40}; Differential_Count tool was used to analyse the matrix of the read counts for differentially expressed genes according to the DESeq2 method\textsuperscript{41}; the Benjamini-Hochberg method was used for multiple hypothesis correction; finally, DE-lncRNAs with adjp under 0.05 were extracted. As the documents of PRJNA286036 study have not mentioned the exact NSCLC subtype of cancer samples, the extracted lncRNAs were queried across circlncRNAnet TCGA LUAD and cBioPortal\textsuperscript{42,43} TCGA LUAD, Provisional, datasets to find and select the ones with significant alterations in LUAD.

2.3 | Data filtration

All of the prepared data were filtered so as to make our downstream analyses more specific. First, the list of lncRNAs selected from the intersection of data retrieved from circlncRNAnet and GEPIA databases was combined with the list of lncRNAs outputted from the RNA-seq data analysis. This combined list was named as the gene library (gene library = (circlncRNAnet DE-lncRNAs ⋂ GEPIA DEGs) ⋃ (NSCLC plasma DE-lncRNAs ⋂ LUAD altered/DE-lncRNAs)). Then, the lncRNAs without RefSeq sequences in the gene library were filtered out in order to lay a firm foundation for our downstream analyses. To this purpose, a list of all RefSeq lncRNAs was retrieved from HGNC BioMart (Table S3)\textsuperscript{44} on 29 January 2018 according to the following options; Filter by genes with RefSeqs accession; Status: Approved; Locus group: non-coding RNA; Locus type: RNA, long non-coding.

2.4 | Survival analysis

Prognostic value of those RefSeq lncRNAs that remained in the last step of the data filtration process was investigated using the GEPIA web server. To this end, the prognostic value of all of the remained RefSeq lncRNAs was analysed across the TCGA LUAD dataset with the default options of GEPIA web server. Lastly, lncRNAs with significant prognostic value (Logrank test \( P \)-value < 0.05) for OS and/or DFS were selected and named as LUAD Prognostic lncRNAs (LUAD Prognostic lncRNAs = (gene library ⋂ RefSeq-lncRNAs) ⋂ LUAD survival-associated lncRNAs). Also, using the GEPIA web server, the expression of LUAD Prognostic lncRNAs (LAProLncRs) was analysed across the LUAD tumour samples.

### Table 1 | lncRNAs with prognostic value in lung adenocarcinoma (LUAD)

| lncRNA symbol | Gene description | Prognostic value | Logrank test \( P \)-value |
|---------------|------------------|-----------------|--------------------------|
| ADAMTS9-AS2   | ADAMTS9 antisense RNA 2 | OS             | 0.00072                  |
| C8orf34-AS1   | C8orf34 antisense RNA 1   | OS             | 0.028                    |
| CADM3-AS1     | CADM3 antisense RNA 1     | OS             | 0.0016                   |
| FAM83A-AS1    | FAM83A antisense RNA 1    | DFS            | 0.0024                   |
| FENDRR        | FOXF1 adjacent non-coding developmental regulatory RNA | OS | 0.0026                  |
| LANCL1-AS1    | LANCL1 antisense RNA 1    | OS             | 0.014                    |
| LINCO0092     | long intergenic non-protein coding RNA 92 | OS | 0.033                    |
| LINCO0467     | long intergenic non-protein coding RNA 467 | OS | 0.0038                   |
| LINCO0857     | long intergenic non-protein coding RNA 857 | OS | 0.032                    |
| LINCO0891     | long intergenic non-protein coding RNA 891 | OS | 0.0013                   |
| LINCO0968     | long intergenic non-protein coding RNA 968 | OS | 0.0021                   |
| LINCO0987     | long intergenic non-protein coding RNA 987 | OS | 0.0023                   |
| LINCO1506     | long intergenic non-protein coding RNA 1506 | OS | 0.035                    |
| MAFG-AS1      | MAFG antisense RNA 1 (head to head) | OS | 0.013                    |
| MIR497HG      | mir-497-195 cluster host gene | OS | 0.037                    |
| RAMP2-AS1     | RAMP2 antisense RNA 1      | DFS            | 0.029                    |
| ROXOF1-AS1    | ROXOF1 antisense RNA 1     | OS             | 0.038                    |
| SNHG6         | small nucleolar RNA host gene 6 | OS | 0.014                    |
| TBX5-AS1      | TBX5 antisense RNA 1       | OS             | 0.017                    |

Abbreviations: DFS, Disease-Free Survival; OS, Overall Survival.
High lncRNA TPM

OP

GH

is a unit of transcript expression and the abbreviation of Transcripts per Million. The plots were achieved using GEPIA web server

FIGURE 2  Association of lncRNAs with OS in LUAD. The association of (A) ADAMTS9-AS2, (B) C8orf34-AS1, (C) CADM3-AS1, (D) FAM83A-AS1, (E) FENDRR, (F) LANC1-AS1, (G) LINC0092, (H) LINC00467, (I) LINC00857, (J) LINC00891, (K) LINC00968, (L) LINC00987, (M) LINC01506, (N) MAFG-AS1, (O) MIR497HG, (P) RHOF1-AS1, (Q) TBX5-AS1, (R) SNHG6. IncRNAs with the OS of LUAD patients. TPM is a unit of transcript expression and the abbreviation of Transcripts per Million. The plots were achieved using GEPIA web server.
FIGURE 3  Altered expression of 19 LAProLncRs. The altered expression of (A) ADAMTS9-AS2, (B) C8orf34-AS1, (C) CADM3-AS1, (D) FAM83A-AS1, (E) FENDRR, (F) LANCL1-AS1, (G) LINC00092, (H) LINC00467, (I) LINC00857, (J) LINC00891, (K) LINC00968, (L) LINC00987, (M) LINC01506, (N) MAFG-AS1, (O) MIR497HG, (P) RAMP2-AS1, (Q) RHOXF1-AS1, (R) SNHG6, (S) TBX5-AS1, lncRNAs in LUAD tumour samples. FC and TPM are the abbreviations of Fold-Change and Transcripts per Million respectively. Box plots were achieved using GEPIA web server.
compared with normal controls to illustrate their expression dysregulations. Additionally, a multivariate Cox regression analysis with adjustments for the clinicopathological features of patients, including tumour stage, gender and smoking history was done to figure out if any of the prognostic lncRNAs in LUAD could be considered as an independent prognostic factor or not. For this purpose, the Kaplan-Meier plotter online software (http://kmplot.com/analysis) was used to perform a multivariate Cox regression analysis on a LUAD microarray study (GSE31210). In this step, a microarray dataset rather than an RNA-Seq one was used to obtain more reliable results.

2.5 Coexpression analysis
The coexpression analysis was done for each lncRNA independently. Different resources of TCGA LUAD processed data were integrated in order to identify high-confident CEGs. To this purpose, first, all of the significantly CEGs with each lncRNA were retrieved from both circlnRNA.net and GEPIA databases and their shared genes were outputted. Then, the intersection of CEGs with the list of all LUAD DEGs was queried $(\cap \text{circlnRNA.net CEGs} \cap \text{GEPIA CEGs}) \cap \text{GEPIA DEGs})$ so as to separate differentially expressed CEGs (DECEGs) (Table S4). Finally, the coexpression networks of lncRNAs with one another and with other DEGs were reconstructed using Cytoscape v3.5.1.

2.6 Functional analysis
A coexpression-based model was applied for the prediction of functional roles of lncRNAs in LUAD. First, the DECEGs of each LAProLncR were used to perform a gene set enrichment analysis for gene ontology-biological process (GO-BP) terms via Enrichr web server. It

![Gene coexpression networks.](image)

**FIGURE 4** Gene coexpression networks. (A) The network of LAProLncRs and their DECEGs; the yellow nodes represent LAProLncRs. (B) The gene coexpression network of LAProLncRs. The intensity of violet node colour is proportional to betweenness centrality score; stronger violet colour indicates higher betweenness centrality score. Red and Blue node borders are indicative of overexpression and underexpression respectively. The width of node border indicates the GEPIA Log2FC; wider border indicates greater Log2FC. The size of violet nodes and their label font size indicate the node degree; bigger violet node and label font size are indicative of higher node degree. The edge colour and width shows the GEPIA PCC; darker and wider edge is indicative of higher GEPIA PCC. PCC is the abbreviation of Pearson Correlation Coefficient. The networks were reconstructed using the Cytoscape software.
should be noted that because SNHG6 was not significantly differentially expressed in LUAD, not only its DECEGs, but all of its CEGs were used for the gene set enrichment analysis. Then, the FuncPred database was used to investigate the association of LAProLncRs with GO-BP terms in normal lung tissue based on the tissue-specific and evolutionary conserved expression data. Finally, the first ranked GO-BP terms of Enrichr (according to the highest combined score) and FuncPred (according to the lowest FDR) as well as their intersection were selected as the most remarkable GO-BP terms and were illustrated as a network using the Cytoscape software. Furthermore, considering the clustered lncRNAs in the lncRNA-GO-BP network, the LncPath R package (https://CRAN.R-project.org/package=LncPath) was used to interrogate the synergistic function of lncRNAs across the KEGG pathways. At last, the DECEGs of synergic lncRNAs were mapped onto the predicted pathway using KEGG Mapper and the resulted pathway was imported into Cytoscape by means of KEGGscape app and enhanced manually. LncPath conducts a random walk strategy followed by applying a weighted Kolmogorov-Smirnov statistic to evaluate the pathways related to the lncRNA sets based on their CEGs.

**2.7 Clinicopathological and demographic analysis**

The differential expression of LAProLncRs among different LUAD stages was analysed using the GEPIA web server. Also, the impact of

![Figure 5](url)
| GO-BP ID   | GO-BP description                                                                 |
|-----------|----------------------------------------------------------------------------------|
| GO:0000184 | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay               |
| GO:0000959 | mitochondrial RNA metabolic process                                               |
| GO:0002474 | antigen processing and presentation of peptide antigen via MHC class I            |
| GO:0003012 | muscle system process                                                              |
| GO:0006119 | oxidative phosphorylation                                                          |
| GO:0006259 | DNA metabolic process                                                              |
| GO:0006285 | base-excision repair, AP site formation                                            |
| GO:0006302 | double-strand break repair                                                         |
| GO:0006310 | DNA recombination                                                                  |
| GO:0006412 | translation                                                                       |
| GO:0006414 | translational elongation                                                           |
| GO:0006415 | translational termination                                                          |
| GO:0006418 | tRNA aminoacylation for protein translation                                        |
| GO:0006520 | cellular amino acid metabolic process                                             |
| GO:0006613 | cotranslational protein targeting to membrane                                      |
| GO:0006614 | SRP-dependent cotranslational protein targeting to membrane                        |
| GO:0006631 | fatty acid metabolic process                                                       |
| GO:0006768 | biotin metabolic process                                                           |
| GO:0007160 | cell-matrix adhesion                                                               |
| GO:0007219 | Notch signalling pathway                                                           |
| GO:0007411 | axon guidance                                                                      |
| GO:0007517 | muscle organ development                                                           |
| GO:0008284 | positive regulation of cell proliferation                                         |
| GO:0008637 | apoptotic mitochondrial changes                                                    |
| GO:0009062 | fatty acid catabolic process                                                       |
| GO:0009127 | purine nucleoside monophosphate biosynthetic process                               |
| GO:0009128 | purine nucleoside monophosphate catabolic process                                 |
| GO:0009158 | ribonucleoside monophosphate catabolic process                                    |
| GO:0009168 | purine ribonucleoside monophosphate biosynthetic process                           |
| GO:0009169 | purine ribonucleoside monophosphate catabolic process                             |
| GO:0010565 | regulation of cellular ketone metabolic process                                   |
| GO:0010631 | epithelial cell migration                                                           |
| GO:0015671 | oxygen transport                                                                   |
| GO:0016042 | lipid catabolic process                                                             |
| GO:0016054 | organic acid catabolic process                                                     |
| GO:0018196 | peptidyl-asparagine modification                                                   |

(Continues)
TABLE 2  (Continued)

| GO-BP ID   | GO-BP description                                      |
|------------|--------------------------------------------------------|
| GO:00070972| protein localization to endoplasmic reticulum          |
| GO:0072011 | glomerular endothelium development                     |
| GO:0072599 | establishment of protein localization to endoplasmic reticulum |
| GO:0090051 | negative regulation of cell migration involved in sprouting angiogenesis |
| GO:0090130 | tissue migration                                        |
| GO:0090132 | epithelium migration                                   |
| GO:0098542 | defense response to other organism                     |
| GO:2000352 | negative regulation of endothelial cell apoptotic process |
| GO:2000738 | positive regulation of stem cell differentiation        |
| GO:2001223 | negative regulation of neuron migration                |

Abbreviations: BP, Biological Process; GO, Gene Ontology.

smoking habit and gender on the expression of prognostic lncRNAs in LUAD was investigated using the Lung Cancer Explorer (http://lce.biohpc.swmed.edu/lungcancer). Lung Cancer Explorer is an online database that provides the exploration of gene expression data from several public lung cancer datasets.

2.8 | Statistical and topological analysis

All of the statistical analyses, except Cox regression analysis, were done using R statistical software (R Development Core Team (2014), freely available at http://www.r-project.org). The multivariate Cox regression analysis was done by the Kaplan-Meier plotter web server. The Pearson correlation coefficient ($R$) $>0.3$ was considered as the significant threshold throughout the study. Also, the $P$-value $<0.05$ was considered statistically significant in all of the analyses. In the context of graph topology, two network metrics including betweenness centrality (a measure of node centrality based on shortest paths) and degree (the number of edges incident to each node) were coincidently employed to determine the hub nodes, whenever possible.

3 | RESULTS

3.1 | Selection of 168 IncRNAs as the gene library

After filtration of the TCGA LUAD DE-IncRNAs, only 164 IncRNAs remained. Also, RNA-seq data analysis resulted in 109 circulating IncRNAs with significant differential abundance ($2 < \log2(FC), \text{adj} < 0.05$) in NSCLC plasma samples compared with normal ones (Table S5). Interestingly, all 109 IncRNAs had lower abundance in NSCLC plasma samples compared with normal samples. Filtration of these 109 IncRNAs through circIncrNA.net and cBioPortal databases indicated that four of the 109 circulating IncRNAs were significantly amplified/overexpressed in TCGA LUAD samples (Data not shown). Altogether, 168 IncRNAs were selected for downstream analyses (Table S6).

3.2 | Presentation of 19 IncRNAs as candidate LUAD biomarkers

Among all IncRNAs in our gene library, only 62 IncRNAs came out as RefSeq IncRNAs after filtration through HGNC RefSeq IncRNAs (Table S7). Subsequently, survival analyses using the GEPIA web server demonstrated that 19 of the 62 RefSeq IncRNAs had significant prognostic values (Logrank test $P$-value $<0.05$) for LUAD (Table 1). Remarkably, one of these IncRNAs, namely SNHG6, was of the IncRNAs with differential abundance between plasma samples of NSCLC patients and healthy controls. Also, Kaplan-Meier plots illustrated that the association of these 19 IncRNAs with OS/DFS of patients is in accordance with the dysregulation of these IncRNAs in TCGA LUAD cancer samples (Figure 2 and Figure S1). Actually, while down-regulated IncRNAs had higher expression levels in patients with higher percentages of OS/DFS, up-regulated IncRNAs had lower expression levels in those patients. Furthermore, the expression analysis of these IncRNAs using the GEPIA web server demonstrated obvious differences in the expression of these 19 IncRNAs between normal and cancer samples (Figure 3).

3.3 | LAProLncRs are coexpressed with several other genes

The coexpression analysis of IncRNAs indicated that they were significantly coexpressed (PCC $>0.3$) with several other DEGs in LUAD (Figure 4A). The coexpression analysis of IncRNAs with other LUAD DEGs also demonstrated that overexpressed and underexpressed IncRNAs do not have common CEGs and tend to cluster in separate modules. According to the topological analysis of the coexpression network, ATIC and JAM2 were identified as the hub nodes in the overexpressed and underexpressed modules respectively. Moreover, 16 of the 19 IncRNAs were significantly coexpressed (PCC $>0.3$) with each other of which FENDRR was the one with the highest degree and betweenness centrality in the IncRNAs coexpression network (Figure 4B).

3.4 | LAProLncRs are involved in several regulatory biological processes

The gene set enrichment analysis of the DECEGs of LAProLncRs indicated that these IncRNAs might be involved in several regulatory biological processes including cancer-related ones (Figure 5; Table 2; Table S8). As depicted in the IncRNA-GO-BP network, some IncRNAs and their associated GO terms were grouped in modules and might work in common biological processes. While C8orf34-AS1 and LINC00467 in Module A were mostly associated with the cellular lipid catabolic processes, SNHG6 and CADM3-AS1 were related to the regulation of protein translation, targeting and localization. On the other hand, IncRNAs in Module B were connected with the biological adhesion processes, cell and tissue migration, apoptosis and signalling pathways including...
Wnt and Notch signalling pathways. Non-modulated IncRNAs were associated with cancer-related biological processes as well; LINC00857 was associated with DNA strand elongation and positive regulation of cell proliferation; MAFG-AS1 with the regulation of DNA protection, repair and recombination; LINC01506 with the regulation of immune system and responses; RHOFX1-AS1 with apoptotic and catabolic processes; LANCL1-AS1 with the regulation of lipid metabolic processes and angiogenesis; MIR497HG with the regulation of endothelium development and migration; and FAM83A-AS1 and LINC00987 were associated with development and morphogenesis. According to the topological analysis of the IncRNA-GO-BP network, GO:0006414 (translational elongation) and GO:0051058 (negative regulation of small GTPase mediated signal transduction) were identified as the hub nodes of Modules A and B respectively. Furthermore, the pathway analysis of Module A and B of the IncRNA-GO-BP network demonstrated that the IncRNAs in Module B could have significant synergistic functions (P-value:0.012; FDR:0.024) in the neuroactive ligand-receptor interaction pathway (Table 3 and Figure S2).

3.5 | The expression of some of the LAProLncRs is associated with clinicopathological and demographic features

The analyses demonstrated that the expression of nine of the 19 LAProLncRs was significantly associated (P-value < 0.05) with different stages of LUAD (Figure 6). Also, the violin plots in Figure 6 indicated that the association of these nine IncRNAs with different stages of LUAD is in accordance with the dysregulation of these IncRNAs in TCGA LUAD cancer samples; while up-regulated IncRNAs usually

---

**FIGURE 6** The expression-stage plot of LAProLncRs. (A) The expression-stage plot of ADAMTS9-AS2 lncRNA. (B) The expression-stage plot of FAM83A-AS1 lncRNA. (C) The expression-stage plot of LANCL1-AS1 lncRNA. (D) The expression-stage plot of LINC00092 lncRNA. (E) The expression-stage plot of LINC00857 lncRNA. (F) The expression-stage plot of LINC00891 lncRNA. (G) The expression-stage plot of MIR497HG lncRNA. (H) The expression-stage plot of SNHG6 lncRNA. (I) The expression-stage plot of TBX5-AS1 lncRNA. The plots were achieved by the GEPIA web server.
had higher expression levels in patients with higher tumour stages, down-regulated lncRNAs had lower expression levels in those patients. Likewise, the expression of four of the 19 LAProLncRs was significantly influenced (P-value < 0.05) by the smoking habit in LUAD and this association was in accordance with the dysregulation of these lncRNAs in TCGA LUAD cancer samples (Figure 7A-D). Furthermore, the expression of three of the 19 LAProLncRs was significantly associated (P-value < 0.05) with the gender of LUAD patients (Figure 7E-G). However, multivariate Cox regression analyses indicated that while the expression level of most of the LAProLncRs and the stage of patients are independent prognostic factors, gender and smoking history do not have independent prognostic value for LUAD (Table 4).

### 4 | DISCUSSION AND CONCLUSION

The aim of this investigation was to systematically examine the diagnostic and predictive value of lncRNAs for LUAD and to annotate their functions by employing a bioinformatic and systems biology approach. Recently, the focus of cancer investigations has shifted from protein-coding genes to non-coding transcripts especially lncRNAs given their diverse regulatory roles on gene expression at the transcriptional and post-transcriptional levels. Although the association of tens of lncRNAs with LUAD has been previously reported, most of them are not annotated and their functions in LUAD development have not been deciphered. Dysregulation of eight of the 19 LAProLncRs including ADAMTS9-AS2, FENDRR, LINC00968, RAMP2-AS1, SNHG6, LINC0092, and TBX5-AS1 in LUAD has been previously demonstrated. Though, the prognostic value of most of these lncRNAs for LUAD patients has not been evaluated. Similarly, the differential abundance of lncRNAs in the plasma of normal and LUAD specimens, which could be used as signatures for diagnosis and prognosis of LUAD, has not yet been examined. Altogether, the detection and characterization of LAProLncRs could help early diagnosis, prognosis and treatment of patients with this deadly disease. In this study, we addressed all of the above issues.

Circulating lncRNAs have recently emerged as novel cancer biomarkers for diagnostic and prognostic purposes. For instance, the circulating lncRNAs NEAT1, ANRIL and SPRY4-IT1 have been suggested as new diagnostic biomarkers for NSCLC. It has been reported that the dysregulation of lncRNAs in plasma is in accordance with their dysregulation in the source tumour tissue. Thus, according to our RNA-Seq data analysis, dysregulated lncRNAs in NSCLC plasma samples could be used for diagnostic purposes and might play important roles in NSCLC development. However, there is a delicate point that is yet ignored regarding the abundance of circulating RNAs. Circulating RNAs originate as a result of different cellular events especially apoptosis and escape from the enzymatic degradation via absorption by extracellular vesicles including apoptotic bodies. Also, it is well known that cancer cells evade apoptosis by employing different strategies.

### TABLE 3 LAProLncRs and their coexpressed genes with synergistic function in the neuroactive ligand-receptor interaction pathway

| DECEG | LncRNA symbol | PCC | Dysregulation in LUAD |
|-------|---------------|-----|-----------------------|
| CHRM1 | FENDRR        | 0.9 | Down-regulated        |
| ADRA1A| ADAMTS9-AS2   | 0.54| Down-regulated        |
| ADRB2 | ADAMTS9-AS2   | 0.59| Down-regulated        |
| ADRB1 | FENDRR        | 0.76| Down-regulated        |
| ADRB2 | FENDRR        | 0.83| Down-regulated        |
| ADRB2 | LINC0092      | 0.58| Down-regulated        |
| ADRB2 | LINC00891     | 0.65| Down-regulated        |
| ADRB2 | LINC00968     | 0.76| Down-regulated        |
| EDNRB | ADAMTS9-AS2   | 0.56| Down-regulated        |
| EDNRB | FENDRR        | 0.92| Down-regulated        |
| EDNRB | TBX5-AS1      | 0.73| Down-regulated        |
| EDNRB | LINC0092      | 0.59| Down-regulated        |
| EDNRB | LINC00891     | 0.6  | Down-regulated        |
| EDNRB | LINC00968     | 0.79| Down-regulated        |
| NMUR1 | FENDRR        | 0.88| Down-regulated        |
| NMUR1 | LINC0092      | 0.65| Down-regulated        |
| NMUR1 | LINC00968     | 0.69| Down-regulated        |
| NMUR1 | RAMP2-AS1     | 0.4 | Down-regulated        |
| NMUR1 | TBX5-AS1      | 0.74| Down-regulated        |
| PTGIR | TBX5-AS1      | 0.79| Down-regulated        |
| S1PR1 | ADAMTS9-AS2   | 0.58| Down-regulated        |
| S1PR1 | FENDRR        | 0.87| Down-regulated        |
| S1PR1 | LINC0092      | 0.58| Down-regulated        |
| S1PR1 | LINC00968     | 0.79| Down-regulated        |
| RXP1  | FENDRR        | 0.88| Down-regulated        |
| RXP1  | RAMP2-AS1     | 0.4 | Down-regulated        |
| RXP1  | LINC00968     | 0.74| Down-regulated        |
| CALCRL| FENDRR        | 0.93| Down-regulated        |
| CALCRL| TBX5-AS1      | 0.74| Down-regulated        |
| CALCRL| LINC0092      | 0.58| Down-regulated        |
| CALCRL| LINC00968     | 0.73| Down-regulated        |
| VIPR1 | FENDRR        | 0.91| Down-regulated        |
| GRIA1 | ADAMTS9-AS2   | 0.59| Down-regulated        |
| GRIA1 | FENDRR        | 0.82| Down-regulated        |
| GRIA1 | TBX5-AS1      | 0.78| Down-regulated        |
| GRIA4 | ADAMTS9-AS2   | 0.53| Down-regulated        |
| GRIA1 | LINC0092      | 0.67| Down-regulated        |
| GRIA4 | LINC0092      | 0.58| Down-regulated        |
| GRIA1 | LINC00891     | 0.66| Down-regulated        |
| GRIA4 | LINC00891     | 0.59| Down-regulated        |
| GRIA1 | LINC00968     | 0.84| Down-regulated        |
| GRIA4 | LINC00968     | 0.74| Down-regulated        |

Abbreviations: DECEGs, differentially expressed coexpressed genes; LUAD, lung adenocarcinoma; PCC, Pearson correlation coefficient.
Consequently, circulating RNAs might have a lower abundance in the plasma of cancer specimens relative to normal ones. Altogether, further studies on the diagnostic and prognostic value of all 109 circulating lncRNAs might represent new potential circulating lncRNA biomarkers as tools for early diagnosis, prognosis and monitoring of treatment response for NSCLC patients. According to our results, one of the 19 LAProLncRs, namely SNHG6, was also dysregulated in NSCLC plasma samples and could possibly be used as a diagnostic and/or prognostic biomarker for non-invasive detection and treatment monitoring of LUAD. In addition, other 18 LAProLncRs could be used as diagnostic and/or prognostic biomarkers in clinical practice as well. Notably, the association of six of the 19 LAProLncRs with lung cancer has been previously confirmed by microarray studies (Table 5). However, there is no report about the other 13 LAProLncRs.

Considering the guilt by association principle, CEGs might share common features. Although application of this principle could readily help prediction of functions and features of unknown genes in

**FIGURE 7** The impact of smoking habit and gender on the expression of LAProLncRs. (A) The impact of smoking habit on ADAMTS9-AS2 expression in LUAD. (B) The impact of smoking habit on FAM83A-AS1 expression in LUAD. (C) The impact of smoking habit on MAFG-AS1 expression in LUAD. (D) The impact of smoking habit on SNHG6 expression in LUAD. (E) The impact of gender on LINC00092 expression in LUAD. (F) The impact of gender on SNHG6 expression in LUAD. (G) The impact of gender on LINK00467 expression in LUAD. The plots were obtained from the Lung Cancer Explorer.
normal cells and tissues, employing this principle to annotate unknown genes in diseased cells is somewhat challenging. Regarding the association of genes and cancer progression, non-differentially expressed genes might not play an active and direct role in the development of tumours. In other words, DE-lncRNAs have common features with their DECEGs and not all of their CEGs. This is a key point that has been ignored in almost all of the studies by far, which may mislead the authors and result in incorrect outcomes and interpretations. Accordingly, we only considered those CEGs of LAProLncRs that were differentially expressed as well, namely DECEGs, in all of the analyses. The results of coexpression analyses illustrate that the overexpressed and underexpressed LAProLncRs are independently clustered with their DECEGs in two big modules. This implies that overexpressed and underexpressed LAProLncRs are involved in different biological processes and networks. Also, hub nodes in the coexpression networks might be driving cancer genes and potential drug targets for the treatment of LUAD. The genes ATIC and JAM2 were identified as the hub nodes in the overexpressed and underexpressed LAProLncRs modules respectively. According to the IGDB.NSCLC database, the dysregulation of ATIC and JAM2 in LUAD is confirmed by microarray studies as well. ATIC can be translocated with ALK, a potential target for the treatment of NSCLC. Also, Pemetrexed, an approved drug for unresectable and metastatic non-squamous NSCLC, is an antifolate that inhibits the

| LncRNA      | Dysregulation (Up/Down) | Overall survival | Multivariate analysis |
|-------------|-------------------------|------------------|----------------------|
|             |                         |                  | Covariate            | HR     | 95%CI   | P-value |
| ADAMTS9-AS2 | Down                    | Lower            | LncRNA expression    | 0.23   | 0.11-0.5 | 0.0002  |
|             |                         |                  | Stage                | 2.8    | 1.39-5.63 | 0.0039  |
|             |                         |                  | Gender               | 1.1    | 0.42-2.87 | 0.8426  |
|             |                         |                  | Smoking history      | 0.9    | 0.34-2.38 | 0.832   |
| FENDRR      | Down                    | Lower            | LncRNA expression    | 0.1    | 0.01-0.74 | 0.0242  |
|             |                         |                  | Stage                | 3.42   | 1.73-6.73 | 0.0004  |
|             |                         |                  | Gender               | 1.07   | 0.44-2.58 | 0.8819  |
|             |                         |                  | Smoking history      | 0.93   | 0.38-2.28 | 0.83    |
| LINCO0092   | Down                    | Lower            | LncRNA expression    | 0.26   | 0.11-0.62 | 0.0022  |
|             |                         |                  | Stage                | 3.4    | 1.71-6.77 | 0.0005  |
|             |                         |                  | Gender               | 1.19   | 0.46-3.08 | 0.7208  |
|             |                         |                  | Smoking history      | 1.15   | 0.43-3.09 | 0.7758  |
| LINCO00467  | Up                      | Higher           | LncRNA expression    | 0.42   | 0.17-1.03 | 0.058   |
|             |                         |                  | Stage                | 3.6    | 1.81-7.16 | 0.0003  |
|             |                         |                  | Gender               | 1.07   | 0.43-2.66 | 0.8839  |
|             |                         |                  | Smoking history      | 0.72   | 0.29-1.84 | 0.4969  |
| LINCO00857  | Up                      | Higher           | LncRNA expression    | 2.78   | 1.4-5.51  | 0.0034  |
|             |                         |                  | Stage                | 3.74   | 1.9-7.38  | 0.0001  |
|             |                         |                  | Gender               | 1.17   | 0.45-3.06 | 0.7474  |
|             |                         |                  | Smoking history      | 0.9    | 0.34-2.39 | 0.8268  |
| LINCO00968  | Down                    | Lower            | LncRNA expression    | 0.29   | 0.12-0.7  | 0.0055  |
|             |                         |                  | Stage                | 2.6    | 1.27-5.34 | 0.0092  |
|             |                         |                  | Gender               | 1.22   | 0.5-2.97  | 0.6559  |
|             |                         |                  | Smoking history      | 1.07   | 0.43-2.66 | 0.8775  |
| MAFG-AS1    | Up                      | Higher           | LncRNA expression    | 1.71   | 0.8-3.68  | 0.1693  |
|             |                         |                  | Stage                | 4.18   | 2.12-8.23 | 0      |
|             |                         |                  | Gender               | 1.05   | 0.42-2.61 | 0.9143  |
|             |                         |                  | Smoking history      | 0.75   | 0.3-1.9   | 0.5491  |
| MIR497HG    | Down                    | Lower            | LncRNA expression    | 0.62   | 0.32-1.22 | 0.1637  |
|             |                         |                  | Stage                | 3.75   | 1.9-7.42  | 0.0001  |
|             |                         |                  | Gender               | 1.15   | 0.45-2.92 | 0.7695  |
|             |                         |                  | Smoking history      | 0.82   | 0.32-2.09 | 0.6722  |

(Continued)
products of \( \text{ATIC} \) and some other genes.\(^{\text{65}} \) Also, polymorphisms in \( \text{ATIC} \), rs12995526 for instance, could impact on the therapeutic efficacy of Pemetrexed-treated patients with LUAD.\(^{\text{66}} \) Moreover, inhibition of \( \text{ATIC} \) or its knockdown by small interfering-RNA (siRNA) is a novel chemoradiosensitization strategy which might enhance the treatment efficacy of LUAD patients.\(^{\text{67}} \)

\( \text{JAM2} \) is a multifunctional transmembrane protein and is involved in the regulation of diverse cellular processes such as cell growth, proliferation, angiogenesis and tumour metastasis. It is reported that \( \text{JAM2} \) is down-regulated in NSCLC\(^{\text{68}} \) and LUAD.\(^{\text{69}} \) Also, Tian et al demonstrated that \( \text{JAM2}, \text{ADARB1}, \text{FENDRR} \) and some other LUAD DEGs might synergistically function in the tumourigenesis of stage I LUAD.\(^{\text{70}} \) Furthermore, Glen et al reported that \( \text{JAM2} \) could be targeted for the treatment of NSCLC.\(^{\text{71}} \) In addition, according to the topological features of the coexpression network of LAProLncRs with each other, FENDRR is the most important node and might essentially contribute to the tumourigenesis of LUAD.

The gene set enrichment analysis demonstrated that most of the LAProLncRs and their associated GO-BP terms are clustered in two modules. The LAProLncRs in Module A are mostly related to protein and lipid regulatory processes especially lipid catabolic processes. Specific lipids play important roles in endoplasmic reticulum stress, intracellular oncogenic signalling and the relation between cancer cells and cells of the tumour microenvironment.\(^{\text{72}} \) Also, it has been shown that the aberrant lipid metabolism promotes prostate cancer\(^{\text{73}} \) and blocking of the lipid catabolism decreases prostate tumour growth.\(^{\text{72}} \) In addition, GO:0006414 (translational elongation) is the hub GO-BP term in Module A and is common among CADM3-AS1, LINC00467 and SNHG6. Translation elongation factors play significant roles in cancer development in a cancer-specific manner. Also, their overexpression predicts poor prognosis in lung cancer.\(^{\text{74}} \) The LAProLncRs in Module B of the lncRNA-GO-BP network are as associated with well-known cancer-related biological processes and signalling pathways and GO:0051058 (negative regulation of small GTPase mediated signal transduction) was identified as the hub GO-BP term in this module. Members of the Rab family of small GTPase superfamily are essential factors in tumourigenesis\(^{\text{75}} \) and their up-regulation is associated with poor prognosis and aggressiveness of lung, breast, ovarian, renal and other cancers.\(^{\text{76}} \) Actually, they play essential roles in the regulation of metabolism, cell-cell adhesion and cell proliferation and migration,\(^{\text{77}} \) which are concordant with other GO-BP terms in Module B. Non-modulated LAProLncRs are connected with cancer-related GO-BP terms as well. These data provide

**Table 4** (Continued)

| LncRNA     | Dysregulation (Up/Down) | Overall survival | Multivariate analysis |
|------------|-------------------------|------------------|----------------------|
|            |                         |                  | Covariate           | HR       | 95% CI     | P-value |
| RAMP2-AS1  | Down                    | Lower            | LncRNA expression   | 0.33     | 0.15-0.73  | 0.006   |
|            |                         |                  | Stage               | 3.6      | 1.82-7.12  | 0.0002  |
|            |                         |                  | Gender              | 1.24     | 0.48-3.23  | 0.6542  |
|            |                         |                  | Smoking history     | 0.91     | 0.34-2.39  | 0.8417  |
| SNHG6      | Up\(^{\text{b}}\)       | Higher           | LncRNA expression   | 0.52     | 0.26-1.04  | 0.0638  |
|            |                         |                  | Stage               | 3.88     | 1.97-7.65  | 0.0001  |
|            |                         |                  | Gender              | 1.25     | 0.5-3.14   | 0.6297  |
|            |                         |                  | Smoking history     | 0.87     | 0.34-2.19  | 0.7626  |
| TBX5-AS1   | Down                    | Lower            | LncRNA expression   | 0.21     | 0.09-0.49  | 0.0004  |
|            |                         |                  | Stage               | 2.57     | 1.27-5.19  | 0.0086  |
|            |                         |                  | Gender              | 1.32     | 0.52-3.34  | 0.5632  |
|            |                         |                  | Smoking history     | 1.13     | 0.43-2.93  | 0.8041  |

Abbreviations: CI, Confidence Interval; HR, Hazard Ratio.
\(^{\text{a}}\)Expression level of the lncRNA in LUAD patients with lower overall survival (OS) compared to patients with higher OS.
\(^{\text{b}}\)Higher expression in tumour vs normal samples but with no significant differential expression.

**Table 5**  The association of six lncRNAs with lung cancer based on microarray studies

| LncRNA symbol | Cancer subtype | Methods               | Reference |
|---------------|----------------|-----------------------|-----------|
| ADAMTS9-AS2   | NSCLC          | Microarray            | 60        |
| FENDRR        | LUAD           | qRT-PCR and RNA-FISH  | 52        |
|               |                | Microarray            | 60        |
|               |                | RNA-seq and Microarray| 33        |
| LINC00857     | Lung cancer    | Microarray            | 61        |
| LINC00968     | NSCLC          | Microarray            | 60        |
|               | LUSC           | RNA-seq and Microarray| 33        |
| LINC00987     | LUAD           | Microarray            | 62        |
| MAFG-AS1      | NSCLC          | Microarray            | 60        |

Abbreviations: NSCLC: Non-Small Cell Lung Cancer; LUSC: Lung Squamous Cell carcinoma; LUAD: Lung Adenocarcinoma; qRT-PCR: Quantitative Reverse Transcription-Polymerase Chain Reaction; RNA-FISH: Fluorescent In situ Hybridization Targeting Ribonucleic Acid Molecules
insights into the functional roles of LAProLncRs in LUAD tumourigenesis. In addition to hub GO-BP terms, the shared terms between LUAD and normal lung tissues (blue edges in Figure 5) should also be considered with a higher priority in future studies. Also, the pathway enrichment analysis demonstrated that the LAProLncRs in Module B might synergistically function in the neuroactive ligand-receptor interaction pathway. The neuroactive ligand-receptor interaction is a methylation-enriched pathway which its association with LUSC, osteosarcoma, breast cancer, colon cancer, pancreatic cancer and hepatocellular carcinoma has been previously reported.

However, further studies are required to decode the precise functional roles of Module B LAProLncRs in this pathway as well as the association of this pathway with LUAD.

The clinicopathological and demographic analyses indicated that the expression level of some of the LAProLncRs is associated with cancer stage, sex and smoking habits in LUAD patients. Besides, the tumour stage is negatively correlated with survival period of NSCLC patients. This implies that the expression level of LAProLncRs could be used as an additional signature for distinguishing between different stages and consequently predicting the survival period of LUAD patients. Also, results of the association analysis of smoking habit with the expression of LAProLncRs are consistent with the results of differential expression analysis. Actually, while down-regulated LAProLncRs have a lower expression level in smoker LUAD patients, up-regulated LAProLncRs have a higher expression level in such patients compared with non-smoker LUAD patients. Furthermore, based on the results of demographic analyses, men might be more vulnerable to LUAD. On the other hand, adjustment of the survival analysis of the expression of LAProLncRs for clinicopathological features of LUAD patients demonstrated that while gender and smoking history are not independent prognostic factors, tumour stage of the patients and the expression level of most of the LAProLncRs have independent prognostic value in LUAD (Table 4).

Collectively, we conducted the most comprehensive systematic analysis and functional annotation, by far, on the prognostic lncRNAs of LUAD and presented 19 lncRNAs as novel LAProLncRs. Several novel biomarkers and drug targets were suggested which might open up new avenues for the early diagnosis, prognosis and treatment of LUAD patients. Also, our results of the differential expression analysis. Actually, while down-regulated LAProLncRs have a lower expression level in smoker LUAD patients, up-regulated LAProLncRs have a higher expression level in such patients compared with non-smoker LUAD patients. Furthermore, based on the results of demographic analyses, men might be more vulnerable to LUAD. On the other hand, adjustment of the survival analysis of the expression of LAProLncRs for clinicopathological features of LUAD patients demonstrated that while gender and smoking history are not independent prognostic factors, tumour stage of the patients and the expression level of most of the LAProLncRs have independent prognostic value in LUAD (Table 4).

Collectively, we conducted the most comprehensive systematic analysis and functional annotation, by far, on the prognostic IncRNAs of LUAD and presented 19 IncRNAs as novel LAProLncRs. Several novel biomarkers and drug targets were suggested which might open up new avenues for the early diagnosis, prognosis and treatment of LUAD patients. Also, our research lays the groundwork for the design of the next studies. However, we faced several limitations in this study that should be noticed in future studies. As we used available online tools with default options in several steps of the project, investigation of the expression level and coexpression of LAProLncRs and their CEGs in different contexts such as age, gender, smoking habit and tumour stage and simultaneous consideration of all of these conditions was not possible. Also, the number of normal and NSCLC plasma samples that we had access to was too low and consequently our results regarding the differential abundance of IncRNAs in the blood might not be robust enough. Additionally, further in silico, in vitro and in vivo assays are required to evaluate the potential of LAProLncRs as biomarkers and/or drug targets for LUAD patients.

ACKNOWLEDGEMENTS
The results shown in this study are in part based upon data generated by the TCGA Research Network: http://cancergenome.nih.gov. The authors thank Ms. Mozdeh Shamoradi for her scientific consultations and Ms. Marzie Samimifar for the proofreading of the English language of the manuscript.

CONFLICT OF INTEREST
The authors have no conflict of interest.

AUTHOR CONTRIBUTIONS
AS: Designed the bioinformatic and systems biology analyses, performed all of the analyses and wrote the first manuscript draft.
ZR: Supervised the whole study and revised the final version of the manuscript.
AN: Designed the bioinformatic and systems biology analyses, supervised the whole study and revised the final version of the manuscript. All authors read and approved the final manuscript.

DATA AVAILABILITY STATEMENT
All datasets generated/analysed for this study are included in the manuscript and the supplementary files.

ORCID
Abbas Salavaty https://orcid.org/0000-0001-9320-5889

REFERENCES
1. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1-19.
2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83:584-594.
3. Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong K-K. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14:535-546.
4. Gridelli C, Rossi A, Carbone DP, et al. Non-small-cell lung cancer. Nat Rev Dis Primers. 2015;1:15009.
5. Qi P, Zhou X-Y, Du X. Circulating long non-coding RNAs in cancer: current status and future perspectives. Mol Cancer. 2016;15:39.
6. Denisenko TV, Budkevich IN, Zhivotovsky B. Cell death-based treatment of lung adenocarcinoma. Cell Death Dis. 2018;9:117.
7. Chen Y-C, Chen J-H, Richard K, Chen P-Y, Christiani DC. Lung adenocarcinoma and human papillomavirus infection. Cancer. 2004;101:1428-1436.
8. Nagy-Mignotte H, Guillem P, Vesin A, et al. Primary lung adenocarcinoma: characteristics by smoking habit and sex. Eur Respir J. 2011;38:1412-1419.
9. X-h S, Qi P, Du X. Long non-coding RNAs in cancer invasion and metastasis. Mod Pathol. 2015;28:4-13.
10. Anastasiadou E, Jacob LS, Slack FI. Non-coding RNA networks in cancer. Nat Rev Cancer. 2017;18:5-18.
11. Hajiri M, Salavaty A. HOTAIR: an oncogenic long non-coding RNA in different cancers. Cancer Biol Med. 2015;12:1-9.

12. Cong Z, Diao Y, Xu Y, et al. Long non-coding RNA linc00665 promotes lung adenocarcinoma progression and functions as ceRNA to regulate AKR1B10-ERK signaling by sponging miR-99. Cell Death Dis. 2019;10:84-.

13. Salavaty A, Motlagh FM, Barabadi M, et al. Potential role of RAB6C-AS1 long noncoding RNA in different cancers. J Cell Physiol. 2018;234:891-903.

14. Herrera-Solorio AM, Armas-López L, Arrieta O, et al. Histone code and long non-coding RNAs (lncRNAs) aberrations in lung cancer: implications in the therapy response. Clin Epigenetics. 2017; 9:98.

15. Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012;150:1107-1120.

16. Bolha L, Ravnik-Glavač M, Glavač D. Long noncoding RNAs as biomarkers in cancer. Dis Markers. 2017;2017:1-14.

17. Gold B, Cankovic M, Fortado LV, Meier F, Gocke CD. Do circulating tumor cells, exosomes, and circulating tumor nucleic acids have clinical utility? A report of the association for molecular pathology. J Mol Diagn. 2015;17:209-224.

18. Savelyeva AV, Kuligina EV, Bariakin DN, et al. Variety of RNAs in peripheral blood cells, plasma, and plasma fractions. Biomed Res Int. 2017;2017:1-10.

19. Lu T, Wang Y, Chen D, Liu J, Jiao W. Potential clinical application of IncRNAs in non-small cell lung cancer. Onco Targets Ther. 2018;11:8045-8052.

20. Zhao B, Xu H, Ai X, et al. Expression profiles of long noncoding RNAs in lung adenocarcinoma. Onco Targets Ther. 2018;11:5383-5390.

21. Zhu TG, Xiao A, Wei Q, Yue M, Zhang LK. Revealing potential long non-coding RNA biomarkers in lung adenocarcinoma using long non-coding RNA-mediated competitive endogenous RNA network. Biorxiv J Med Biol Res. 2017;50:e6297-e.

22. Liao M, Liu Q, Li B, Liao W, Xie W, Zhang Y. A group of long noncoding RNAs identified by data mining can predict the prognosis of lung adenocarcinoma. Cancer Sci. 2018;109:4033-4044.

23. Lin Y, Leng Q, Zhan M, Jiang F. A plasma long noncoding RNA signature for early detection of lung cancer. Transl Oncol. 2018;11:1225-1231.

24. Chen X. KATZLDA: KATZ measure for the IncRNA-disease association prediction. Sci Rep. 2015;5:16840-.

25. Chen X, Yan G-Y. Novel human IncRNA-disease association inference based on IncRNA expression profiles. Bioinformatics. 2013;29:2617-2624.

26. Chen X, Yan CC, Zhang X, You Z-H. Long non-coding RNAs and complex diseases: from experimental results to computational models. Brief Bioinform. 2017;18:558-576.

27. Chen X, Sun Y-Z, Guan N-N, et al. Computational models for IncRNA function prediction and functional similarity calculation. Brief Funct Genomics. 2018;18(1):58-82.

28. Zhang J, Liu S-C, Luo X-H, et al. Exosomal long noncoding RNAs are differentially expressed in the cervicovaginal lavage samples of cervical cancer patients. J Clin Lab Anal. 2016;30:1116-1121.

29. Perron U, Provero P, Molineris I. In silico prediction of IncRNA function using tissue specific and evolutionary conserved expression. BMC Bioinformatics. 2017;18:144.

30. Yona G, Dirks W, Rahman S, Lin DM. Effective similarity measures for expression profiles. Bioinformatics. 2006;22:1616-1622.

31. Schmitt AM, Chang HY. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29:452-463.

32. Miozzi L, Piro RM, Rosa F, et al. Functional annotation and identification of candidate disease genes by computational analysis of normal tissue gene expression data. PLoS ONE. 2008;3:e2439.

33. Chen W-J, Tang R-X, He R-Q, et al. Clinical roles of the aberrantly expressed IncRNAs in lung squamous cell carcinoma: a study based on RNA-sequencing and microarray data mining. Oncotarget. 2017;8:61282-61304.

34. Wu S-M, Liu H, Huang P-J, et al. circlncRNAanet: an integrated web-based resource for functional networks of long or circular forms of noncoding RNAs. Gigascience. 2018;7:1-10.

35. Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45:W98-W102.

36. Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29:15-21.

37. Trappnell C, Williams BA, Pertea G, et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 2010;28:511-515.

38. Volders P-J, Verheggen K, Menschaert G, et al. An update on LNCipedia: a database for annotated human IncRNA sequences. Nucleic Acids Res. 2015;43:D174-D180.

39. Volders P-J, Menschaert K, Wang X, et al. LNCipedia: a database for annotated human IncRNA transcript sequences and structures. Nucleic Acids Res. 2013;41:D246-D251.

40. Anders S, Pyl PT, Huber W. HTSeq—a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015;31:166-169.

41. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550-.

42. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013;6:pl1.

43. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2012;2:401-404.

44. Gray KA, Yates B, Seal RL, Wright MW, Bruford EA. Genenames. org: the HGNC resources in 2015. Nucleic Acids Res. 2015;43(D1):D1079-D1085.

45. Gyorffy B, Surowiak P, Budczies J, Lanczyk A. Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer. PLoS ONE. 2013;8:e82241.

46. Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13:2498-2504.

47. Kuleshov MV, Jones MR, Rouillard AD, et al. Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016;44:W90-W97.

48. Chen EY, Tan CM, Kou Y, et al. Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics. 2013;14:128-.

49. Kanehisa M, Furumichi M, Tanabe M, Sato Y, Morishima K. KEGG: new perspectives on genomes, pathways, diseases and drugs. Nucleic Acids Res. 2017;45:D353-D361.

50. Nishida K, Ono K, Kanaya S, Takahashi K. KEGGscapes: a Cytoscape app for pathway data integration. F1000Research. 2014;3:344.

51. Li S, Li B, Zheng Y, Li M, Shi L, Pu X. Exploring functions of long noncoding RNAs across multiple cancers through co-expression network. Sci Rep. 2017;7:754-.
non-small cell lung cancer: a bioinformatic analysis based on miRNA microarray, GEO and TCGA. Oncol Lett. 2018;15:9487-9497.

54. Li Y, Wang Z, Nair A, et al. Comprehensive profiling of lincRNAs in lung adenocarcinoma of never smokers reveals their roles in cancer development and prognosis. Genes (Basel). 2017;8(11):321.

55. Liang R, Xiao G, Wang M, et al. SNHG6 functions as a competing endogenous RNA to regulate EZF7 expression by sponging miR-26a-5p in lung adenocarcinoma. Biomed Pharmacother. 2018;107:1434-1446.

56. Qiao F, Li N, Li W. Integrative bioinformatics analysis reveals potential long non-coding RNA biomarkers and analysis of function in non-smoking females with lung cancer. Med Sci Monit. 2018;24:5771-5778.

57. Suraj S, Dhar C, Srivastava S. Circulating nucleic acids: an analysis of their occurrence in malignancies. Biomed Rep. 2017;6:8-14.

58. Fritz JV, Heintz-Buschart A, Ghosal A, et al. Sources and functions of extracellular small RNAs in human circulation. Annu Rev Nutr. 2016;36:301-336.

59. Fernald K, Kurokawa M. Evading apoptosis in cancer. Trends Cell Biol. 2013;23:620-633.

60. Yu H, Xu Q, Liu F, Ye X, Wang J, Meng X. Identification and validation of long noncoding RNA biomarkers in human non-small cell lung carcinomas. J Thorac Oncol. 2015;10:645-654.

61. Wang L, He Y, Liu W, et al. Non-coding RNA LINCO00857 is predictive of poor patient survival and promotes tumor progression via cell cycle regulation in lung cancer. Oncotarget. 2016;7:11487-11499.

62. Xu G, Chen JJ, Pan Q, et al. Noncoding RNA expression profiles of lung adenocarcinoma ascertained by microarray analysis. PLoS ONE. 2014;9:e104044-e.

63. Kao S, Shiao C-K, Gu D-L, et al. IGDB NSCLC: integrated genomic database of non-small cell lung cancer. Nucleic Acids Res. 2012;40:D972-D977.

64. La Madrid AM, Campbell N, Smith S, Cohn SL, Salgia R. Targeting ALK: a promising strategy for the treatment of non-small cell lung cancer, non-Hodgkin's lymphoma, and neuroblastoma. Target Oncol. 2012;7:199-210.

65. Walter R, Mairinger FD, Werner R, et al. Folic-acid metabolism and DNA-repair phenotypes differ between neuroendocrine lung tumors and associate with aggressive subtypes, therapy resistance and outcome. Oncotarget. 2016;7:20166-20179.

66. Woo HI, Kim JA, Jung HA, et al. Correlation of genetic polymorphisms with clinical outcomes in pemetrexed-treated advanced lung adenocarcinoma patients. Pharmacogenomics. 2015;16:383-391.

67. Liu X, Paila UD, Teraoka SN, et al. Identification of ATIC as a Novel Target for Chemoradiosensitization. Int J Radiat Oncol Biol Phys. 2018;100:162-173.

68. Zhao H, Yu H, Martin TA, Teng XU, Jiang WG. The role of JAM-B in cancer and cancer metastasis (Review). Oncol Rep. 2016;36:3-9.

69. Jin X, Liu X, Li X, Guan Y. Integrated analysis of DNA methylation and mRNA expression profiles data to identify key genes in lung adenocarcinoma. Biomed Res Int. 2016;2016:1-9.

70. Tian Z, Wen S, Zhang Y, et al. Identification of dysregulated long non-coding RNAs/microRNAs/mRNAs in TNM 1 stage lung adenocarcinoma. Oncotarget. 2017;8:51703-51718.

71. Weiss GJ, Kingsley C. Pathway targets to explore in the treatment of non-small cell lung cancer. J Thorac Oncol. 2008;3:1342-1352.

72. Beloribi-Djefaflia S, Vasseur S, Guillamond F. Lipid metabolic re-programming in cancer cells. Oncogenesis. 2016;5:e189.

73. Deep G, Schlaepfer I. Aberrant lipid metabolism promotes prostate cancer: role in cell survival under hypoxia and extracellular vesicles biogenesis. Int J Mol Sci. 2016;17:1061.

74. Hassan MK, Kumar D, Naik M, Dixit M. The expression profile and prognostic significance of eukaryotic translation elongation factor factors in different cancers. PLoS ONE. 2018;13:e0191377.

75. Chua C, Tang BL. The role of the small GTPase Rab31 in cancer. J Cell Mol Med. 2015;19:1-10.

76. Wang S, Hu C, Wu F, He S. Rab25 GTPase: Functional roles in cancer. Oncotarget. 2017;8:64591-64599.

77. Ioannou MS, McPherson PS. Regulation of cancer cell behavior by the small GTPase Rab13. J Biol Chem. 2016;291:9929-9937.

78. Zhao Y, Xue F, Sun J, et al. Genome-wide methylation profiling of the different stages of hepatitis B virus-related hepatocellular carcinoma development in plasma cell-free DNA reveals potential biomarkers for early detection and high-risk monitoring of hepatocellular carcinoma. Clin Epigenetics. 2014;6:30.

79. Li Q, Hou J, Hu Z, Gu B, Shi Y. Multiple mutations of lung squamous cell carcinoma shared common mechanisms. Oncotarget. 2016;7.

80. Xu J, Li D, Cai Z, et al. An integrative analysis of DNA methylation in osteosarcoma. J Bone Oncol. 2017;9:34-40.

81. Huan J, Wang L, Xing L, et al. Insights into significant pathways and gene interaction networks underlying breast cancer cell line MCF-7 treated with 17β-estradiol (E2). Gene. 2014;533:346-355.

82. Liu Y, Wang L, Wang B, Yue M, Cheng Y. Pathway analysis based on attractor and cross talk in colon cancer. Dis Markers. 2016;2016:1-7.

83. Wei P, Tang H, Li D. Insights into pancreatic cancer etiology from pathway analysis of genome-wide association study data. PLoS ONE. 2012;7:e46887.

84. Zhang J, Gold KA, Lin HY, et al. Relationship between tumor size and survival in non-small-cell lung cancer (NSCLC): an analysis of the surveillance, epidemiology, and end results (SEER) registry. J Thorac Oncol. 2015;10:682-690.

SUPPORTING INFORMATION

Additional supporting information may be found online in the Supporting Information section at the end of the article.